• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Scientific Officer Mcnamara Peter was granted 15,141 shares, increasing direct ownership by 107% to 29,329 units (SEC Form 4)

    2/6/25 4:05:14 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TECX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    McNamara Peter

    (Last) (First) (Middle)
    C/O TECTONIC THERAPEUTIC, INC.
    490 ARSENAL WAY, SUITE 210

    (Street)
    WATERTOWN MA 02472

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Tectonic Therapeutic, Inc. [ TECX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Scientific Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    02/04/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 02/04/2025 A 15,141(1) A $0 29,329 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Employee Stock Option (Right to Buy) $48.01 02/04/2025 A 27,530 (2) 02/03/2035 Common Stock 27,530 $0 27,530 D
    Explanation of Responses:
    1. These shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The shares shall vest in 3 equal annual installments on each of February 4, 2026, February 4, 2027 and February 4, 2028, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
    2. The shares subject to the option vest in 48 equal monthly installments beginning on March 4, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
    /s/ Daniel Lochner, Attorney-in-Fact 02/06/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $TECX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TECX

    DatePrice TargetRatingAnalyst
    4/21/2025$51.00Outperform
    Mizuho
    11/20/2024$65.00Outperform
    Raymond James
    8/22/2024$55.00Overweight
    Wells Fargo
    6/26/2024Overweight
    Piper Sandler
    6/24/2024Buy
    TD Cowen
    More analyst ratings

    $TECX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025

      Data confirmed TX45's tolerability profile and improvements in left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction ("PH-HFpEF")In new echocardiographic analysis, TX45 treatment resulted in sustained hemodynamic effects for 29 daysTX45 improved cardiac and pulmonary hemodynamics in PH-HFpEF patients across a range of left ventricular ejection fractions ("LVEF"), including LVEF≥50% and LVEF 41-49% WATERTOWN, Mass., May 17, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic") today announced the complete results from Part A of the Phase 1b clinical trial of TX45 in pat

      5/17/25 10:40:00 AM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tectonic Therapeutic Announces First Quarter 2025 Financial Results and Recent Business Highlights

      Interim analysis from the TX45 Phase 1b Part A trial demonstrated meaningful improvements in both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction ("PH-HFpEF")Full results from the Phase 1b Part A trial will be presented on May 17, 2025 at the European Society of Cardiology (ESC) Heart Failure Congress in Belgrade, SerbiaPart B of the TX45 Phase 1b trial initiated in March with topline results expected in the second half of 2025Ongoing TX45 APEX Phase 2 trial continues to enroll with topline results expected in 2026Cash and cash equivalents were $306.2 million as of March 31, 2025, including

      5/8/25 4:01:00 PM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tectonic Therapeutic To Present on May 15th, 2025 at the Bank of America Securities Health Care Conference

      WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors ("GPCRs"), today announced that Alise Reicin, MD, President and Chief Executive Officer, will present at the Bank of America Securities 2025 Health Care Conference taking place in Las Vegas on May 12-15, 2025. Bank of America Securities Health Care Conference Date:Thursday, May 15th, 2025Time:9:20am PDTFormat:Corporate PresentationPresenter:Alise Reicin, MD, President and Chief Executive OfficerWebcast:Link The

      5/7/25 8:00:00 AM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TECX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mizuho initiated coverage on Tectonic Therapeutic with a new price target

      Mizuho initiated coverage of Tectonic Therapeutic with a rating of Outperform and set a new price target of $51.00

      4/21/25 8:39:06 AM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Raymond James initiated coverage on Tectonic Therapeutic with a new price target

      Raymond James initiated coverage of Tectonic Therapeutic with a rating of Outperform and set a new price target of $65.00

      11/20/24 7:46:41 AM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wells Fargo initiated coverage on Tectonic Therapeutic with a new price target

      Wells Fargo initiated coverage of Tectonic Therapeutic with a rating of Overweight and set a new price target of $55.00

      8/22/24 7:34:40 AM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TECX
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Tectonic Therapeutic Inc.

      SCHEDULE 13G/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)

      5/15/25 2:24:51 PM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Tectonic Therapeutic Inc.

      SCHEDULE 13G/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)

      5/12/25 10:43:30 AM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B3 filed by Tectonic Therapeutic Inc.

      424B3 - Tectonic Therapeutic, Inc. (0001681087) (Filer)

      5/8/25 4:33:19 PM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TECX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Springer Timothy A bought $2,299,015 worth of shares (141,923 units at $16.20), increasing direct ownership by 0.49% to 4,334,846 units (SEC Form 4)

      4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

      4/11/25 6:12:08 PM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Springer Timothy A bought $8,550,000 worth of shares (500,000 units at $17.10), increasing direct ownership by 2% to 4,313,558 units (SEC Form 4)

      4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

      4/9/25 5:38:10 PM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Springer Timothy A bought $39,999,977 worth of shares (789,294 units at $50.68), increasing direct ownership by 3% to 4,226,058 units (SEC Form 4)

      4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

      2/7/25 4:21:19 PM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TECX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Tectonic Therapeutic Inc.

      SC 13G/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)

      11/14/24 4:05:11 PM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Tectonic Therapeutic Inc.

      SC 13D/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)

      10/28/24 6:08:43 PM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Tectonic Therapeutic Inc.

      SC 13D/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)

      10/24/24 5:12:09 PM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TECX
    Financials

    Live finance-specific insights

    See more
    • Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF

      TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction ("PH-HFpEF"), supporting endpoints and patient population in ongoing APEX Phase 2 clinical trialInterim analysis demonstrated that TX45 achieved 17.9% reduction in Pulmonary Capillary Wedge Pressure ("PCWP") in the total study population of PH-HFpEF and >30% reduction in Pulmonary Vascular Resistance ("PVR") in Combined pre- and post-capillary PH ("CpcPH"), a subpopulation with more severe diseaseTX45 was well tolerated in patients with PH-HFpEF with no serious or severe adverse events, significant hypotension, or immune rel

      1/30/25 6:30:00 AM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tectonic Therapeutic Announces Third Quarter 2024 Financial Results and Recent Business Highlights

      Patient enrollment in the Phase 1b hemodynamic trial remains ahead of expectation, with topline results now expected in late Q1'2025 or early Q2'2025First subject dosed with TX000045 ("TX45") in APEX Phase 2 clinical trial in early October, with topline results expected in 2026Development Candidate TX002100 ("TX2100") selected for second program targeting patients with Hereditary Hemorrhagic Telangiectasia (HHT)Cash and cash equivalents were $159.1 million as of September 30, 2024, expected to provide cash runway into mid-2027 WATERTOWN, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic", or "the Company"), a clinical-stage biotechnology compan

      11/7/24 4:01:00 PM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tectonic Therapeutic Announces Second Quarter 2024 Financial Results and Recent Business Highlights

      TX45 advances into Phase 2 clinical trial for patients with Group 2 PH-HFpEF with first site activated and screening open in August 2024Received U.S. Investigational New Drug (IND) clearance for lead program, TX45 in July 2024Completed reverse merger with AVROBIO in June 2024, including concurrent private placement of $130.7 millionCash and cash equivalents were $185.1 million as of June 30, 2024, prior to the payment of accrued transaction and related expenses of approximately $14.4 million, are expected to provide cash runway into mid-2027 WATERTOWN, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic", or "the Company"), a clinical-stage biotech

      8/14/24 4:01:00 PM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TECX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Springer Timothy A bought $2,299,015 worth of shares (141,923 units at $16.20), increasing direct ownership by 0.49% to 4,334,846 units (SEC Form 4)

      4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

      4/11/25 6:12:08 PM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Springer Timothy A bought $8,550,000 worth of shares (500,000 units at $17.10), increasing direct ownership by 2% to 4,313,558 units (SEC Form 4)

      4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

      4/9/25 5:38:10 PM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Mcguire Terrance sold $8,550,000 worth of shares (500,000 units at $17.10) (SEC Form 4)

      4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

      4/7/25 5:02:43 PM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care